Optimal design of personalized prostate cancer therapy using Infinitesimal Perturbation Analysis

The standard treatment for advanced prostate cancer is hormone therapy in the form of continuous androgen suppression (CAS), which unfortunately frequently leads to resistance and relapse. An alternative scheme is intermittent androgen suppression (IAS), in which patients are submitted to cycles of treatment (in the form of androgen deprivation) and off-treatment periods in an alternating manner. In spite of extensive recent clinical experience with IAS, the design of ideal protocols for any given patient remains a challenge. The level of prostate specific antigen (PSA) is frequently monitored to determine when patients will be taken off therapy and when therapy will resume. In this work, we propose a threshold-based policy for optimal IAS therapy design that is parameterized by lower and upper PSA threshold values and is associated with a cost metric that combines clinically relevant measures of therapy success. We use a Stochastic Hybrid Automaton (SHA) model of prostate cancer evolution under IAS and perform Infinitesimal Perturbation Analysis (IPA) to adaptively adjust PSA threshold values so as to improve therapy outcomes. We also apply this methodology to clinical data from real patients, and obtain promising results and valuable insights for personalized IAS therapy design.